Vals

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vals

Quick Facts

Property Description
Active ingredient Valsartan
Form Oral Solid (Tablets, Capsules)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common purpose To manage high blood pressure
Origin Synthetic Compound (Nonpeptide Antagonist)

Defining Valsartan: What Type of Medicine is Vals?

The medication commonly referred to as Vals contains the active ingredient Valsartan, a prescription-only, synthetic compound classified primarily as an Angiotensin II Receptor Blocker (ARB). This designation places it firmly within the broader class of Antihypertensive Agents. Valsartan functions by selectively blocking the AT₁ receptors, thereby targeting a crucial mechanism within the body’s Renin-Angiotensin-Aldosterone System (RAAS), which is essential for regulating blood pressure and fluid balance. The medication functions to achieve targeted receptor blockade. The drug is prepared for use both as a single-ingredient product for monotherapy and often as a fixed-dose combination product alongside a second compound.

Valsartan's Composition and Dosage Form

The core component of the medicine is the sole active ingredient, Valsartan, which is a nonpeptide antagonist derived from the tetrazole chemical structure. This compound’s specific chemical composition differentiates it from older classes of blood pressure medication, such as the ACE inhibitors. Valsartan is supplied for oral administration and is primarily presented in solid dosage form(s), typically as compressed tablets or capsules. The high-level composition consists of the active substance, Valsartan, combined with necessary inactive excipients required to manufacture the stable, ingestible preparation.

What is the General Purpose of Vals?

The fundamental general purpose of Valsartan is to counteract the effects of high systemic pressure by promoting widespread vessel relaxation and assisting in the modulation of circulatory volume. A typical, neutral use scenario for Valsartan is the sustained, long-term management of high blood pressure. By accomplishing a sustained blood pressure lowering effect, the medicine offers essential cardioprotective benefits, mitigating the long-term strain placed upon the entire cardiovascular system by persistent pressure imbalances.

Regulatory References

  1. ACE inhibitors

What side effects are possible with Vals?

Possible Side Effects and Safety Information

Valsartan's official safety profile, documented by regulatory authorities, details adverse reactions organized by frequency and the body system affected. These classifications establish the known risk landscape of the medicine.


Frequency-Classified Adverse Reactions

Side effects are categorized based on their rate of occurrence in clinical trials and postmarketing experience. Reactions categorized as Common often include dizziness, headache, and fatigue. Those deemed Uncommon may include vertigo, cough, diarrhea, and joint pain (arthralgia). Less frequently documented or post-marketing events, categorized as Rare or Very Rare, involve serious reactions and laboratory changes.


System-Organ Classes and Serious Reactions

Officially listed effects involve several systems, including the Nervous System (headache, dizziness), Vascular Disorders (hypotension), and Metabolism and Nutrition Disorders (hyperkalemia, or increased serum potassium). Serious adverse reactions explicitly documented in the regulatory labeling include Angioedema (severe swelling of the face, lips, and throat) and Acute Renal Failure, which requires specific monitoring.


Population-Specific Safety Considerations

The most critical safety constraint is the contraindication in pregnancy. Valsartan is officially documented to cause injury and death to the developing fetus and must be discontinued immediately upon detection of pregnancy. Furthermore, its use is not recommended in patients with severe hepatic impairment. Patients with severe heart failure or renal artery stenosis require careful safety monitoring of renal function and potassium levels due to the risk of changes in kidney function.


Safety Restrictions

Official labeling notes that the concomitant use of Valsartan with other Angiotensin System agents (known as dual blockade) is associated with an increased risk of severe hypotension, hyperkalemia, and changes in renal function.

Overdose and Emergency Response

The official regulatory documents state that overexposure to Valsartan primarily results in manifestations related to excessive low blood pressure. The principal documented overdose presentation is profound hypotension, which may be clinically recognized as severe dizziness or syncope (fainting).

When overdose is suspected, regulatory labeling mandates that the individual seek immediate medical attention. This action involves contacting emergency services or a Poison Control center without delay.

The overdose profile highlights the risk of severe physiological outcomes, including Acute Renal Failure and dangerously high potassium levels (Hyperkalemia). For this reason, official guidance requires close monitoring of renal function and serum potassium during observation.

Management of overexposure is strictly symptomatic and supportive treatment. For persistent hypotension, regulatory instructions describe placing the patient in the supine position and, if necessary, administering an intravenous infusion of normal saline. A specific constraint is that no specific antidote is known, and Valsartan is not removed by hemodialysis.

Patients who are volume-depleted (e.g., due to severe vomiting or diuretic use) are noted in regulatory documents to be particularly susceptible to symptomatic hypotension following overexposure.

Therapeutic Uses of Vals

Valsartan, an angiotensin II receptor blocker (ARB), is a medication that is commonly used in the management of certain cardiovascular conditions. Its supportive therapeutic role contributes to improved comfort during periods of heightened symptoms associated with cardiovascular conditions.

The medication is relevant for easing symptoms linked to organ-specific functional stress in several conditions. These therapeutic domains include conditions presenting with systemic or localized discomfort, such as hypertension (high blood pressure) in adults and pediatric patients, heart failure, and contexts involving acute or episodic changes, like those following myocardial infarction. In these clinical scenarios, valsartan supports the patient during difficult episodes by easing distress. The overall approach contributes to easing the overall symptom burden in contexts involving heightened systemic burden.

Quick Fact: Relief for symptoms related to heightened physiological activity.

“Valsartan is applied in addressing conditions marked by increased physiological stress, helping patients cope more steadily with symptom fluctuations.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Valsartan

Valsartan is an angiotensin II receptor blocker (ARB) used to treat hypertension and heart failure. Eligibility for its use is strictly defined by regulatory guidance.

Contraindicated Groups

Use of valsartan is contraindicated in patients with a known hypersensitivity to the drug or any of its components. It is also strictly prohibited during the second and third trimesters of pregnancy due to the risk of fetal harm; discontinuation must occur as soon as pregnancy is detected. Additionally, it must not be used concurrently with aliskiren in patients with Diabetes Mellitus or in those with renal impairment (GFR less than 60 mL/ min/1.73 m^2).

Restricted or Not Recommended Use

The medicine is generally not recommended for:

  • Children under one year of age.
  • Nursing mothers; a decision must be made to either stop breastfeeding or discontinue the drug.

Special caution and close monitoring are required when valsartan is administered to patients with severe renal impairment or those who are severely volume-depleted, as these conditions require specific clinical management. No dose adjustment is typically needed for patients with mild to moderate liver or kidney issues, or for the elderly.

What should I know about interactions with other medicines?

Valsartan's officially documented interaction profile is focused on additive pharmacodynamic effects and modifications to drug exposure, as structured in government regulatory documents.

Pharmacodynamic and Substance Interactions

Co-administration with agents that increase serum potassium, such as potassium-sparing diuretics, potassium supplements, or salt substitutes, carries the regulatory-documented risk of hyperkalemia (elevated serum potassium). Combining Valsartan with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may result in a documented reduction of the blood pressure-lowering effect and an increased risk of renal impairment.

Dual inhibition of the Renin-Angiotensin System (RAS) through co-administration with other agents, such as ACE inhibitors, increases the risk of renal impairment, hypotension, and hyperkalemia. Use with Aliskiren is formally contraindicated in patients with diabetes due to these risks. The heightened risk associated with NSAIDs is noted to be particularly relevant in elderly, volume-depleted, or renal-compromised patients.

Exposure and Other Interactions

Co-administration with Lithium has resulted in officially documented increases in serum Lithium concentrations and toxicity due to reduced clearance of Lithium. Food is a documented factor in absorption; administration with a meal results in a reduction in Valsartan’s absorption by approximately 40%. Regulatory documents indicate that no clinically significant interactions are expected with Cytochrome P450 (CYP) enzymes, reflecting the drug's low metabolism. There are no mandatory timing separation rules in the official prescribing information.

Mechanism of Action

Valsartan, an Angiotensin II Receptor Blocker (ARB), acts by targeting the Renin-Angiotensin-Aldosterone System (RAAS). The drug's mechanism is defined by its selective and competitive antagonism of the Angiotensin II type 1 ( AT1) receptor. This receptor is the principal mediator of the hormone Angiotensin II's actions on vascular smooth muscle and the adrenal gland. By physically blocking the binding of Angiotensin II to the AT1 receptor, Valsartan prevents the subsequent intracellular signaling that triggers cellular contraction and aldosterone release. This antagonistic interaction modulates the entire RAAS cascade, limiting downstream effects that influence systemic vascular resistance and renal fluid handling. The resulting physiological consequence of the blockade is an alteration in vascular tone, leading to the relaxation and widening of blood vessels (vasodilation), and a diminution of AT1-mediated signaling effects on renal salt and water reabsorption.

Dosage and Administration Information

Official Administration and Dosing Principles

Valsartan is approved for oral administration as film-coated tablets. The medicine may be taken with or without food as the gastrointestinal absorption is not significantly affected by meal consumption.

Dosing Frequency and Titration

The required dosing frequency is strictly dependent on the condition being addressed. For the long-term management of high blood pressure, administration is typically once daily. However, protocols for heart failure and post-myocardial infarction management stipulate the dose must be divided and administered twice daily to maintain consistent systemic levels.

Instructions mandate distinct dosage ranges by context. For hypertension, the usual starting dose is 80 mg or 160 mg once daily, with a maximum daily dose set at 320 mg. Treatment for heart failure begins with a low dose of 40 mg twice daily and requires a protocol of gradual dose titration over several weeks to reach a target maintenance dose of 160 mg twice daily.

Special Use Conditions

The dosage is adjusted for specific populations; for example, the dose for pediatric patients with hypertension is determined by body weight, beginning at 1.3 mg per kilogram once daily. Furthermore, when a prepared oral suspension is used, it is not bioequivalent to the tablet and must not be substituted on a milligram-for-milligram basis. Patients with mild to moderate renal or hepatic impairment generally do not require an initial dosage modification.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Valsartan


Evidence for Use in High Blood Pressure (Hypertension)

Research exploring Valsartan's use in conditions like high blood pressure primarily involves large, long-term Randomized Controlled Trials (RCTs). These studies were designed to evaluate the drug's effect in adults, including those with other cardiovascular risk factors. Trials monitored whether changes in systolic and diastolic blood pressure were observed over time, as well as the rates of major cardiovascular outcomes (such as heart attacks or strokes).

Findings described patterns of blood pressure measurements across the observed populations. The comparative evidence is lacking regarding Valsartan's direct use against every alternative blood pressure drug. The follow-up durations for all outcomes are finite, meaning evidence related to very long-term outcomes remains limited.


Evidence for Use in Heart Failure

The evidence base related to Valsartan's use in heart failure comes from large, international placebo-controlled trials. Researchers studied outcomes such as hospitalization for heart failure and death from any cause in patients already receiving standard care. Findings described the patterns in heart failure-related hospitalization rates that were observed across the study groups.

Evidence indicates that certainty remains low for patterns associated with its use in combination with both an ACE inhibitor and a beta-blocker. In one major trial, the combination was associated with specific risk patterns that led to increased study discontinuations.


Evidence Following Myocardial Infarction (Post-MI)

Research in patients who recently had a heart attack involved large, active-controlled Randomized Controlled Trials. The main objective was to examine outcomes related to death from any cause, as well as the incidence of events like subsequent non-fatal heart attacks and hospitalization for heart failure. The research primarily examined whether outcomes were consistent with those observed using the established standard of care (ACE inhibitor).

What remains uncertain is the long-term duration of observed patterns beyond the typical two-year observation period of the major trials. The results apply only to the specific high-risk populations studied, who had specific functional measures or clinical presentations immediately post-MI.


What the Research Landscape Shows About Gaps

Data for long-term outcomes and for specific small subgroups are limited. Research has been conducted on pediatric patients, but specific data describing isolated outcomes for older adults in major trials may be limited. The evidence base describes group patterns observed in the studies; the research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Vals (FAQ)


Q: How does taking Vals affect kidney function over time?

Regulatory documents indicate that Valsartan can potentially lead to impaired renal function (reduced kidney performance) in specific vulnerable patients, such as those with existing severe heart failure. For these individuals, blood tests for renal function are typically monitored periodically.


Q: Can Vals be used for conditions other than high blood pressure?

Yes, official documents indicate that Valsartan is approved for several uses. Beyond high blood pressure (hypertension), it is also indicated for the treatment of heart failure and to help reduce cardiovascular risk in patients who have recently experienced a heart attack (post-myocardial infarction).


Q: Is it true that Vals is commonly taken once a day?

The required dosing frequency is determined by the condition being treated. While it is typically administered once daily for the long-term management of high blood pressure, protocols for other uses, like heart failure, generally involve administration twice daily.


Q: How long does it typically take for Vals to start lowering blood pressure?

Clinical pharmacology data shows that the medicine reaches its peak concentration in the body approximately 2 to 4 hours after the tablet is taken. However, for the full effect on blood pressure, official documents indicate that it may take several weeks of consistent use.


Q: Do patients generally feel any different right after starting Vals?

Some patients may experience common adverse reactions, such as dizziness, headache, or fatigue, particularly when first starting treatment. Caution is noted when changing body position, such as when standing up, to mitigate the potential for lightheadedness.


Q: What are the food or drink restrictions while taking Vals?

Valsartan tablets can be taken with or without food, although taking it with a meal can reduce the amount of the drug absorbed into the body. Official labeling includes a warning for the co-administration of alcohol (ethanol), noting the potential for an additive blood pressure lowering effect.


Q: Can Vals affect a person's ability to drive or operate machinery?

Official labeling advises that the ability to drive or operate machinery may be affected due to the potential for side effects like dizziness or fatigue, especially when starting treatment or after a change in dosage.


Q: Why is Vals sometimes prescribed with another blood pressure drug?

Official documents state that Valsartan is approved for use in treating high blood pressure alone or in combination with other medicines. Combining it with another agent is a medical strategy used when a single medication is not enough to achieve the required level of blood pressure control.


Q: Are there specific vitamins or supplements that are known to interact with Vals?

Yes, a documented interaction exists for potassium supplements and salt substitutes containing potassium. Taking these alongside Valsartan increases the regulatory-documented risk of developing hyperkalemia (elevated potassium levels in the blood).


Q: Does Vals have a 'Black Box Warning' listed in the official documents?

The most serious safety concern listed in regulatory documents is a Boxed Warning regarding Fetal Toxicity. Official information strictly states that Valsartan can cause injury and death to the developing fetus and must be discontinued immediately upon detection of pregnancy.


Q: Is it normal to have mild swelling in the ankles when first taking Vals?

Swelling in the face, fingers, or lower legs (edema) is categorized as a less common effect in official adverse reaction lists. Significant or sudden swelling, particularly if related to fluid retention or kidney changes, is not a common expectation and should be reported to a healthcare provider.


Q: Is a frequent side effect mentioned for Vals a change in taste?

A change or disturbance in taste (dysgeusia) is generally considered a rare adverse reaction for Valsartan. This has been reported during postmarketing experience, which means it was identified after the medicine was approved and released.


Q: If I miss a planned time for Vals, what does the official leaflet say to do?

Regulatory guidance advises that if a dose is missed, the patient should take it as soon as they remember. However, if it is nearly time for the next scheduled dose, the patient should skip the missed dose to avoid taking a double dose and return to their regular schedule.


Q: Are there any specific heart conditions where Vals is not recommended?

Valsartan is approved for heart failure, but precautions are noted. Patients with conditions such as severe heart failure or renal artery stenosis require close medical safety monitoring of their blood pressure, kidney function, and potassium levels.


Q: What are the key safety considerations for people with diabetes taking Vals?

Valsartan is formally contraindicated (meaning its use is strictly advised against) for patients who have diabetes and are also taking the medicine Aliskiren. Official sources warn that this combination increases the risk of hypotension, hyperkalemia, and kidney issues.


Q: Does the time of day matter when taking Vals, according to official guidance?

Official prescribing information does not stipulate a mandatory time of day for when to take the medicine. Consistency in timing from day to day is typically recommended to maintain stable blood pressure control.


Q: Are there any warnings about sunlight exposure while taking Vals?

While Valsartan alone is not commonly linked to photosensitivity, some related medicines, including combination products containing Valsartan, do carry warnings about increased sensitivity to sunlight. General caution regarding skin protection is always advisable.


Q: Is a dry mouth or increased thirst listed as a possible effect of Vals?

Dry mouth and increased thirst have been reported in official adverse reaction summaries. These effects are generally classified as less common or rare when using Valsartan.


Q: What official information is available about Vals and weight changes?

Official adverse reaction reporting includes weight gain as a less common side effect. Sudden or unexplained weight gain may indicate fluid retention or changes in kidney function and should be reported to a healthcare provider.


Q: How quickly do the benefits of Vals wear off after stopping the medication?

The medicine has an average elimination half-life of about 6 hours. This is the time it takes for the concentration of the drug to be reduced by half in the body. The duration of the therapeutic effect will begin to diminish as the drug is gradually eliminated.


Q: Is it common for people to switch from another medicine to Vals?

Valsartan is officially indicated for use in heart failure patients who are unable to tolerate other medicines like ACE inhibitors. This indicates that switching between drug classes (e.g., from an ACE inhibitor to Valsartan, an ARB) is a recognized part of clinical treatment protocols.


Q: Are there different brand names that contain the drug Vals?

Yes, Valsartan is the generic name for the active ingredient. It is sold under the brand name Diovan and may also be found in combination products where it is paired with other active medicines.


Q: Is the medication Vals also available as a generic drug?

Yes, the medication Valsartan is available as a generic drug. Generic medicines contain the same active ingredient and are regulated by government bodies to meet the same quality and effectiveness standards as the original brand name medicine.


Q: Are there special warnings for patients with a history of angioedema when using Vals?

Yes, official warnings state that Valsartan is not recommended for re-administration to patients who have previously developed the severe swelling known as angioedema while taking the drug. The warning also notes that a history of angioedema with other medicines, such as ACE inhibitors, is a consideration.

How should Vals be stored and disposed of?

Valsartan storage and disposal requirements are dictated by regulatory labeling to maintain potency and ensure safety.

Storage Conditions

Valsartan tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The prepared oral suspension has temperature-dependent stability limits; it must be stored either under refrigeration (2 C to 8 C) for up to 75 days, or at room temperature (below 30 C) for up to 30 days. The suspension must not be frozen and must be kept in a glass bottle with a child-resistant cap.

Safety and Disposal

All valsartan medicine must be kept out of the sight and reach of children. The official recommendation for disposal of unused or expired product is via a drug take-back program. Valsartan is not on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vals found in:

A-Z Index: